Clinical Trial Update: Atezolizumab Trial in Endometrial Cancer - AtTEnd [Phase 3]

View source ↗

Summary

Phase 3 trial of atezolizumab in endometrial cancer (AtTEnd) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Endometrial Cancer | Phase 3 | Status: COMPLETED